Charlene McDanal

11.9k citations

24 papers · 3.6k indexed · 4 hit papers · h-index 19

Virology top 0.1%
- HIV Research and Treatment 20
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 9
- SARS-CoV-2 and COVID-19 Research 3
Immunology top 2%
- Immune Cell Function and Interaction 7
- T-cell and Retrovirus Studies 3
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 5
Hepatology top 5%
Molecular Biology
- vaccines and immunoinformatics approaches 2
Epidemiology
- Herpesvirus Infections and Treatments 2

Co-authors: Thomas J. Matthews Carl Wild A J Langlois D C Shugars Dani P. Bolognesi Kashi Javaherian J R Rusche Terrence G. Oas
Cited by: Virology Infectious Diseases Immunology
Journals: Proceedings of the National Academy of Sciences (8 papers)The Journal of Experimental Medicine (2 papers)The Journal of Immunology (2 papers)
Partner nations: United States Italy South Korea

In The Last Decade

Charlene McDanal

23 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Cell Host & Microbe
1994 Proceedings of the National Academy of Sciences
1989 Proceedings of the National Academy of Sciences
1988 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Charlene McDanal

Since Specialization

Citations

This map shows the geographic impact of Charlene McDanal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene McDanal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene McDanal more than expected).

Fields of papers citing papers by Charlene McDanal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene McDanal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene McDanal. The network helps show where Charlene McDanal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Charlene McDanal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charlene McDanal Line = papers co-authored together Charlene McDanal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation Scientific Reports ·Yunda Huang,Oleg Borisov,Jia Jin Kee,Lindsay N. Carpp,Terri Wrin,Suqin Cai,Marcella Sarzotti‐Kelsoe,Charlene McDanal,Amanda Eaton,Rolando Pajón,John Hural,Christine M. Posavad,Katherine Gill,Shelly Karuna,Lawrence Corey,M. Juliana McElrath,Peter B. Gilbert,Christos J. Petropoulos,David C. Montefiori	2021	20
2	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccinesbreakdown → Cell Host & Microbe ·Xiaoying Shen,Haili Tang,Charlene McDanal,Kshitij Wagh,Will Fischer,James Theiler,Hyejin Yoon,Dapeng Li,Barton F. Haynes,Kevin O. Sanders,S. Gnanakaran,Nicolas Hengartner,Rolando Pajón,Gale Smith,Gregory M. Glenn,Bette Korber,David C. Montefiori	2021	222
3	SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines SSRN Electronic Journal ·Xiaoying Shen,Haili Tang,Charlene McDanal,Kshitij Wagh,Will Fischer,James Theiler,Hyejin Yoon,Dapeng Li,Barton F. Haynes,Kevin O. Saunders,S. Gnanakaran,Nicolas Hengartner,Rolando Pajón,Gale Smith,Filip Dubovsky,Gregory M. Glenn,Bette Korber,David C. Montefiori	2021	0
4	Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms Bioorganic & Medicinal Chemistry Letters ·Jun Tang,Stacey A. Jones,Jerry Jeffrey,Sónia Miranda,Cristin M. Galardi,David M. Irlbeck,Kevin Brown,Charlene McDanal,Brian A. Johns	2017	19
5	Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase PLoS Biology ·Kushol Gupta,Vesa Turkki,Scott Sherrill-Mix,Young Sun Hwang,Grant Eilers,Louis J. Taylor,Charlene McDanal,Ping Wang,David P. Temelkoff,Robert T. Nolte,Emile J. Velthuisen,Jerry Jeffrey,Gregory D. Van Duyne,Frederic D. Bushman	2016	52
6	In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc The Journal of Clinical Pharmacology ·James F. Demarest,Sara S. Sparks,Kathleen Schell,Shiro Shibayama,Charlene McDanal,Fang Lei,Kimberly K. Adkison,Anne Shachoy‐Clark,Stephen C. Piscitelli	2008	10
7	A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago Proceedings of the National Academy of Sciences ·Farley Cleghorn,Noreen Jack,Jean K. Carr,Robert J. Edwards,Bisram Mahabir,Anne Sill,Charlene McDanal,Shanon M. Connolly,Damon H. Goodman,R. Q. Bennetts,Thomas R. OʼBrien,Kent J. Weinhold,C Bartholomew,William A. Blattner,Michael Greenberg	2000	52
8	Herpesvirus Saimiri Transformation of HIV Type 1 Suppressive CD8 ⁺ Lymphocytes from an HIV Type 1-Infected Asymptomatic Individual AIDS Research and Human Retroviruses ·Simon F. Lacey,Kent J. Weinhold,Chin‐Ho Chen,Charlene McDanal,Coreen Oei,Michael Greenberg	1998	17
9	Random Copolymers Containing Specific Ratios of Negatively Charged and Aromatic Amino Acids Bind V3 Disulfide Loop and Neutralize Diverse HIV Type 1 Isolates AIDS Research and Human Retroviruses ·Kashi Javaherian,Charlene McDanal	1995	10
10	Induction of HIV Type 1 Neutralizing and env -CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins AIDS Research and Human Retroviruses ·Benjamin Rovinski,Lauren Rodrigues,SHI XIAN CAO,FEI-LONG YAO,Ursula McGuinness,Charles Sia,George A. Cates,Susan Zolla‐Pazner,SYLWIA KARWOWSKA,Thomas J. Matthews,Charlene McDanal,John R. Mascola,Michel Klein	1995	19
11	A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion Journal of Virology ·Chen‐Hsin Chen,Thomas J. Matthews,Charlene McDanal,Dani P. Bolognesi,Michael Greenberg	1995	146
12	Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proceedings of the National Academy of Sciences ·Carl Wild,J W Dubay,Teresa Greenwell,T. Baird,Terrence G. Oas,Charlene McDanal,Eric Hunter,Thomas J. Matthews	1994	180
13	Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. The Journal of Experimental Medicine ·Barton F. Haynes,L O Arthur,P. Frost,Thomas J. Matthews,A J Langlois,T J Palker,Mary Kate Hart,Richard M. Scearce,Dawn Jones,Charlene McDanal	1993	15
14	Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. The Journal of Immunology ·Barton F. Haynes,J.V. Torres,A J Langlois,Dani P. Bolognesi,M B Gardner,T J Palker,Richard M. Scearce,Dawn Jones,M. Anthony Moody,Charlene McDanal,(unknown)	1993	35
15	A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proceedings of the National Academy of Sciences ·Carl Wild,Terrence G. Oas,Charlene McDanal,Dani P. Bolognesi,Thomas J. Matthews	1992	418
16	Alteration of HIV-1 Infectivity and Neutralization by a Single Amino Acid Replacement in the V3 Loop Domain AIDS Research and Human Retroviruses ·Lucinda A. Ivanoff,David J. Looney,Charlene McDanal,Jane F. Morris,Flossie Wong‐Staal,A J Langlois,Stephen R. Petteway,Thomas J. Matthews	1991	82
17	Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. The Journal of Experimental Medicine ·F Celada,Caterina Cambiaggi,J Maccari,Samuele E. Burastero,Timothy J. Gregory,Eric J. Patzer,Joanna C. Porter,Charlene McDanal,Thomas J. Matthews	1990	58
18	Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. The Journal of Immunology ·Mary Kate Hart,T J Palker,Thomas J. Matthews,A J Langlois,Nicholas W. Lerche,M E Martin,Richard M. Scearce,Charlene McDanal,D P Bolognesi,Barton F. Haynes	1990	73
19	Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.breakdown → Proceedings of the National Academy of Sciences ·Kashi Javaherian,A J Langlois,Charlene McDanal,Kerstin Ross,Larry Eckler,C L Jellis,Albert T. Profy,J R Rusche,D P Bolognesi,Scott D. Putney	1989	538
20	Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.breakdown → Proceedings of the National Academy of Sciences ·J R Rusche,Kashi Javaherian,Charlene McDanal,J Petro,D L Lynn,R Grimaila,A J Langlois,Robert C. Gallo,L O Arthur,Peter J. Fischinger	1988	568

About Charlene McDanal

Charlene McDanal is a scholar working on Virology, Infectious Diseases and Immunology, having authored 24 papers that have together received 3.6k indexed citations. Recurring topics across this work include HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (9 papers), Immune Cell Function and Interaction (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), SARS-CoV-2 and COVID-19 Research (3 papers), T-cell and Retrovirus Studies (3 papers), vaccines and immunoinformatics approaches (2 papers) and Herpesvirus Infections and Treatments (2 papers). The work is most often cited by research in Virology (2.8k citations), Infectious Diseases (1.9k citations) and Immunology (1.2k citations). Charlene McDanal has collaborated with scholars based in United States, Italy and South Korea. Frequent co-authors include Thomas J. Matthews, Carl Wild, A J Langlois, D C Shugars, Dani P. Bolognesi, Kashi Javaherian, J R Rusche, Terrence G. Oas, D P Bolognesi and L O Arthur. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact